Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hugh McCullough

Physician Assistant South Boston, VA Physician Assistant

NPI 1891068052 CMS profile 10621271

2210 Wilborn Ave, South Boston, VA 24592

Open in the dashboard

General payments

$2,258

104 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hugh McCullough of South Boston, VA is reported in the CMS Open Payments database as having received $2,258 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $797 28
2024 General $595 22
2023 General $529 34
2022 General $102 7
2021 General $235 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hugh McCullough
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Hugh McCullough were reported at $797. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Hugh McCullough Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $235 $132 $37–$438 $132
2022 $102 $155 $48–$522 $149
2023 $529 $167 $52–$557 $160
2024 $595 $178 $55–$600 $164
2025 $797 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $779 22 payments
  2. GlaxoSmithKline, LLC. $503 32 payments
  3. Amgen Inc. $216 13 payments
  4. Regeneron Healthcare Solutions, Inc. $149 9 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $136 2 payments
  6. Novartis Pharmaceuticals Corporation $120 7 payments
  7. Mylan Specialty L.P. $108 5 payments
  8. Verona Pharma, Inc. $66 3 payments
  9. Philips Electronics North America Corporation $65 4 payments
  10. Viatris Specialty LLC $36 2 payments
  11. Other $81 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,258 104 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE Respiratory $432 7 payments
  2. TRELEGY ELLIPTA $342 28 payments
  3. FASENRA $203 10 payments
  4. TEZSPIRE Inflammation $193 12 payments
  5. DUPIXENT $149 9 payments
  6. YUPELRI $143 7 payments
  7. Kerendia $136 2 payments
  8. BREZTRI $116 6 payments
  9. ENTRESTO $104 6 payments
  10. WAINUA $95 1 payment
  11. Other $448 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

86

Median for Physician Assistant: 241

Drug cost

$12,630

Median for Physician Assistant: $4,110

Branded share of claims

44.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $12,053
Amiodarone Hcl Generic 18 $282
Cefuroxime Cefuroxime Axetil Brand 18 $215
Prednisone Generic 19 $55
Spironolactone Generic 11 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $227
  • Amgen Inc. $89
$316 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $52
$52 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $50
$50 — —
YUPELRI
  • Mylan Specialty L.P. $42
$42 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record